Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lin Shen

Showing results (1521-1530 of 1,553) with videos related to

Pageof 156
Sort By:
Advances in Therapy|September 9, 2020
Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO TrialJin Li, Weijian Guo, Yuxian Bai, et al.
Cancer Communications (London, England)|October 19, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II studyZhi Peng, Tianshu Liu, Jia Wei, et al.
Oncotargets and Therapy|August 19, 2021
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal CancerShukui Qin, Rui-Hua Xu, Lin Shen, et al.
Clinical Colorectal Cancer|October 27, 2016
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC StudyAnn-Lii Cheng, Gerardo Cornelio, Lin Shen, et al.
Cell Regeneration (London, England)|January 14, 2025
Standard: Human gastric organoidsFan Hong, Ronghui Tan, Ting Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2015
Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficitsShu-Sheng Jiao, Xiu-Qing Yao, Yu-Hui Liu, et al.
Cancer Immunology, Immunotherapy : CII|July 5, 2024
Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancersZhenghang Wang, Siyuan Cheng, Yanhong Yao, et al.
Neuroendocrinology|July 11, 2018
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine TumoursEric Raymond, Matthew H Kulke, Shukui Qin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2023
Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in ChinaJian Li, Jun Zhang, Yanqiao Zhang, et al.
Cell Regeneration (London, England)|December 27, 2024
Standard: Human gastric cancer organoidsRonghui Tan, Fan Hong, Ting Wang, et al.
Pageof 156

Showing results (1521-1530 of 1,553) with videos related to

Sort By:
Pageof 156
Advances in Therapy|September 9, 2020
Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO TrialJin Li, Weijian Guo, Yuxian Bai, et al.
Cancer Communications (London, England)|October 19, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II studyZhi Peng, Tianshu Liu, Jia Wei, et al.
Oncotargets and Therapy|August 19, 2021
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal CancerShukui Qin, Rui-Hua Xu, Lin Shen, et al.
Clinical Colorectal Cancer|October 27, 2016
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC StudyAnn-Lii Cheng, Gerardo Cornelio, Lin Shen, et al.
Cell Regeneration (London, England)|January 14, 2025
Standard: Human gastric organoidsFan Hong, Ronghui Tan, Ting Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2015
Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficitsShu-Sheng Jiao, Xiu-Qing Yao, Yu-Hui Liu, et al.
Cancer Immunology, Immunotherapy : CII|July 5, 2024
Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancersZhenghang Wang, Siyuan Cheng, Yanhong Yao, et al.
Neuroendocrinology|July 11, 2018
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine TumoursEric Raymond, Matthew H Kulke, Shukui Qin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2023
Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in ChinaJian Li, Jun Zhang, Yanqiao Zhang, et al.
Cell Regeneration (London, England)|December 27, 2024
Standard: Human gastric cancer organoidsRonghui Tan, Fan Hong, Ting Wang, et al.
Pageof 156